knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 17:02:28 - browse：47784

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Stem cell treatment guidelines are released by FDA

hotspot

WSS

FTC sues over Novant Health acquisition of two N.C. hospitals

Bernie Sanders is gearing up to subpoena pharma CEOs

NIH nominee Bertagnolli will get October confirmation hearing

Amazon on where the company's health care bets are headed next

Amazon on where the company's health care bets are headed next

The 10 drugs up first for Medicare price negotiation

hotspot

knowledge

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biogen walks away from Aduhelm, years after polarizing approval

After affirmative action ruling, medical educators look to 'holistic review'

NIH nominee Bertagnolli will get October confirmation hearing

Bright Health sells Medicare Advantage business to Molina

FTC sues over Novant Health acquisition of two N.C. hospitals

Supreme Court strikes down use of affirmative action

Crinetics acromegaly drug succeeds in late

Trump demands the U.S. pay no more for drugs than other countries … again

House transparency, PBM reform bill gains bipartisan support

focus

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Stem cell treatment guidelines are released by FDA

FTC sues over Novant Health acquisition of two N.C. hospitals

Syphilis numbers in the United States reach record heights

Pancreatic cancer early detection could be helped by AI

Merck, Johnson & Johnson CEOs will testify on high drug prices

focus

explore

hotspot

focus